Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01598090 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 881
- Enrollment target
NCT01598090 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 881 participants.
The verdict
NCT01598090, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 881 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.
Interventions
- DRUG Ribavirin
- DRUG Telaprevir
- BIOLOGICAL Peginterferon Lambda-1a
- BIOLOGICAL Peginterferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 881 participants |
| Start Date | 2012-06-14 |
| Est. Completion | 2015-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01598090
The ClinicalTrials.gov registry entry for NCT01598090 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 881 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01598090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01598090 about?
NCT01598090 is a clinical study titled "Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir". The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.
What is the current status of trial NCT01598090?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 881 participants. The study started on 2012-06-14. Estimated completion is 2015-05-15.
What interventions are being tested in trial NCT01598090?
The interventions under investigation include: Ribavirin (DRUG), Telaprevir (DRUG), Peginterferon Lambda-1a (BIOLOGICAL), Peginterferon Alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT01598090?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.